Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nkarta
Biotech
Nkarta's blood cancer CAR stalls again, driving deprioritization
The response rate fell away sharply in the latest update, promoting the NK cell therapy developer to mothball the program.
Nick Paul Taylor
Mar 22, 2024 9:11am
Volatile day for CAR-T biotechs after FDA reveals safety review
Nov 28, 2023 4:35pm
Nkarta moves cell therapy into autoimmune trials, lays off staff
Oct 18, 2023 3:21am
Ex-Nkarta exec Nadir Mahmood to lead UCSF spinout Rezo
Sep 20, 2023 7:00am
EMD Serono taps new COO—Chutes & Ladders
Jul 7, 2023 9:30am
Nkarta's cell therapy needs specific preconditioning
Jun 27, 2023 11:02am